<p>Progyny（纳斯达克股票代码：PGNY - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 的股票研究分析师将评级从 “买入” 下调至 “持有”。</p>
<ul>
<li>3 只你可能从未听说过的最佳股票</li>
</ul>
<p>其他几家研究公司也对 PGNY 发表了评论。KeyCorp 将 Progyny 的股票评级从 “行业中性” 上调至 “超配”，并在 11 月 11 日的研究报告中设定了 30.00 美元的目标价。Canaccord Genuity Group 将 Progyny 的目标价从 23.00 美元上调至 26.00 美元，并在 11 月 17 日的报告中给予该公司 “持有” 评级。摩根大通将 Progyny 的目标价从 25.00 美元上调至 26.00 美元，并在 11 月 11 日的研究报告中给予该公司 “中性” 评级。巴克莱在 12 月 8 日的研究报告中开始覆盖 Progyny，给予 “超配” 评级和 29.00 美元的目标价。最后，Weiss Ratings 在周一的研究报告中重申了对 Progyny 股票的 “持有（c）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，Progyny 目前的共识评级为 “适度买入”，平均目标价为 27.50 美元。</p>
<p><strong>查看我们最新的 Progyny 股票报告</strong></p>
<h2>Progyny 股价上涨 1.8%</h2>
<p>纳斯达克 PGNY 周五开盘价为 26.63 美元。该公司的 50 日简单移动平均为 23.08 美元，200 日简单移动平均为 22.55 美元。Progyny 的 12 个月低点为 13.96 美元，12 个月高点为 27.51 美元。该公司的市值为 23 亿美元，市盈率为 42.27，市盈增长比率为 2.06，贝塔值为 0.97。</p>
<p>Progyny（纳斯达克股票代码：PGNY - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为 0.45 美元，超出分析师共识预期的 0.39 美元，超出幅度为 0.06 美元。该公司季度收入为 3.1335 亿美元，而共识预期为 2.9923 亿美元。Progyny 的净利润率为 4.46%，股本回报率为 10.71%。与去年同期相比，该公司的季度收入增长了 9.3%。在去年同期，该公司每股收益为 0.11 美元。Progyny 将其 2025 财年的指导目标设定为 1.790-1.820 美元的每股收益，并将 2025 年第四季度的指导目标设定为 0.370-0.400 美元的每股收益。整体来看，卖方分析师预测 Progyny 在当前财年将发布 0.6 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席执行官 Peter Anevski 在 11 月 13 日的交易中购买了 79,500 股该股票。每股平均购买价格为 24.29 美元，总交易额为 1,931,055.00 美元。购买完成后，首席执行官直接持有该公司 680,251 股，价值 16,523,296.79 美元。这代表其持股比例增加了 13.23%。该交易已在向 SEC 提交的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Mark S. Livingston 在 11 月 17 日的交易中出售了 21,303 股公司的股票。每股平均售价为 25.50 美元，总价值为 543,226.50 美元。交易完成后，首席财务官直接持有该公司 48,358 股，价值 1,233,129 美元。这代表其持股比例减少了 30.58%。该销售的披露信息可在 SEC 文件中找到。内部人士在过去三个月内出售了价值 561,691 美元的 22,046 股公司股票。公司内部人士持有公司 9.40% 的股份。</p>
<h2>对 Progyny 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Nordea Investment Management AB 在第二季度将其在 Progyny 的持股增加了 0.6%。Nordea Investment Management AB 目前持有 183,362 股该公司股票，价值 4,052,000 美元，此前在上个季度又购买了 1,140 股。Cresset Asset Management LLC 在第二季度将其在 Progyny 的持股增加了 715.3%。Cresset Asset Management LLC 目前持有 85,053 股该公司股票，价值 1,871,000 美元，此前在上个季度又收购了 74,621 股。Voya Investment Management LLC 在第一季度将其在 Progyny 的持股增加了 258.2%。Voya Investment Management LLC 目前持有 185,495 股该公司股票，价值 4,144,000 美元，此前在该期间又收购了 133,703 股。Millennium Management LLC 在第一季度将其在 Progyny 的持股增加了 7.5%。Millennium Management LLC 目前持有 1,302,890 股该公司股票，价值 29,107,000 美元，此前在上个季度又购买了 90,367 股。最后，Acadian Asset Management LLC 在第一季度将其在 Progyny 的持股增加了 243.6%。Acadian Asset Management LLC 目前持有 205,650 股该公司股票，价值 4,589,000 美元，此前在该期间又购买了 145,802 股。机构投资者持有公司 94.93% 的股份。</p>
<h2>关于 Progyny</h2>
<p>（获取免费报告）</p>
<p>Progyny, Inc 是一家总部位于纽约的生育福利管理公司，与雇主和健康计划合作，设计和管理全面的家庭建设项目。该公司的数字健康平台整合了临床专业知识、患者支持工具和数据分析，帮助会员导航生育治疗，从体外受精（IVF）和卵子冷冻到代孕和收养。通过关注基于结果的护理，Progyny 旨在提高成功率，同时控制客户的成本。</p>
<p>Progyny 的核心产品是其专有的 Smart Cycle®福利，将临床、情感和后勤支持整合为一个整体。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Progyny</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>Nike 在盈利上超出预期，但在中国市场面临挑战并遭遇关税</li>
<li>低市盈率成长股：开启投资机会</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>股票中的跳空上涨意味着什么？如何利用跳空</li>
<li>2026 年四只高潜力 ETF：小盘股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 Progyny 吗？</h2>
<p>在考虑 Progyny 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Progyny 并不在名单上。</p>
<p>虽然 Progyny 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PGNY

<p>华尔街禅将 Progyny（纳斯达克代码：PGNY）的评级从 “买入” 下调至 “持有”。其他分析师的评级各不相同，KeyCorp 将其评级上调至 “增持”，而 Canaccord Genuity 则维持 “持有” 评级。Progyny 的股票开盘价为 26.63 美元，市值为 23 亿美元。近期的内部交易包括首席执行官 Peter Anevski 购买股票和首席财务官 Mark S. Livingston 出售股票。机构投资者已调整在该公司的持股比例</p>

<p>Progyny (NASDAQ:PGNY - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Saturday.</p>
<div class="lb-trans"><p>Progyny（纳斯达克股票代码：PGNY - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 的股票研究分析师将评级从 “买入” 下调至 “持有”。</p>
</div><ul>
<li>3 Best Stocks to Buy That You’ve Probably Never Heard Of</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只你可能从未听说过的最佳股票</li>
</ul>
</div><p>Several other research firms have also commented on PGNY. KeyCorp upgraded shares of Progyny from a &#34;sector weight&#34; rating to an &#34;overweight&#34; rating and set a $30.00 price objective for the company in a research note on Tuesday, November 11th. Canaccord Genuity Group upped their target price on Progyny from $23.00 to $26.00 and gave the company a &#34;hold&#34; rating in a report on Monday, November 17th. JPMorgan Chase &amp; Co. increased their price target on Progyny from $25.00 to $26.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, November 11th. Barclays initiated coverage on Progyny in a research report on Monday, December 8th. They issued an &#34;overweight&#34; rating and a $29.00 price objective on the stock. Finally, Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of Progyny in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Progyny presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $27.50.</p>
<div class="lb-trans"><p>其他几家研究公司也对 PGNY 发表了评论。KeyCorp 将 Progyny 的股票评级从 “行业中性” 上调至 “超配”，并在 11 月 11 日的研究报告中设定了 30.00 美元的目标价。Canaccord Genuity Group 将 Progyny 的目标价从 23.00 美元上调至 26.00 美元，并在 11 月 17 日的报告中给予该公司 “持有” 评级。摩根大通将 Progyny 的目标价从 25.00 美元上调至 26.00 美元，并在 11 月 11 日的研究报告中给予该公司 “中性” 评级。巴克莱在 12 月 8 日的研究报告中开始覆盖 Progyny，给予 “超配” 评级和 29.00 美元的目标价。最后，Weiss Ratings 在周一的研究报告中重申了对 Progyny 股票的 “持有（c）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，Progyny 目前的共识评级为 “适度买入”，平均目标价为 27.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Progyny</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Progyny 股票报告</strong></p>
</div><h2>Progyny Trading Up 1.8%</h2>
<div class="lb-trans"><h2>Progyny 股价上涨 1.8%</h2>
</div><p>NASDAQ PGNY opened at $26.63 on Friday. The business has a fifty day simple moving average of $23.08 and a 200 day simple moving average of $22.55. Progyny has a 12 month low of $13.96 and a 12 month high of $27.51. The firm has a market capitalization of $2.30 billion, a P/E ratio of 42.27, a PEG ratio of 2.06 and a beta of 0.97.</p>
<div class="lb-trans"><p>纳斯达克 PGNY 周五开盘价为 26.63 美元。该公司的 50 日简单移动平均为 23.08 美元，200 日简单移动平均为 22.55 美元。Progyny 的 12 个月低点为 13.96 美元，12 个月高点为 27.51 美元。该公司的市值为 23 亿美元，市盈率为 42.27，市盈增长比率为 2.06，贝塔值为 0.97。</p>
</div><p>Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.06. The firm had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. As a group, sell-side analysts predict that Progyny will post 0.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Progyny（纳斯达克股票代码：PGNY - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为 0.45 美元，超出分析师共识预期的 0.39 美元，超出幅度为 0.06 美元。该公司季度收入为 3.1335 亿美元，而共识预期为 2.9923 亿美元。Progyny 的净利润率为 4.46%，股本回报率为 10.71%。与去年同期相比，该公司的季度收入增长了 9.3%。在去年同期，该公司每股收益为 0.11 美元。Progyny 将其 2025 财年的指导目标设定为 1.790-1.820 美元的每股收益，并将 2025 年第四季度的指导目标设定为 0.370-0.400 美元的每股收益。整体来看，卖方分析师预测 Progyny 在当前财年将发布 0.6 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Peter Anevski bought 79,500 shares of the stock in a transaction on Thursday, November 13th. The shares were purchased at an average cost of $24.29 per share, for a total transaction of $1,931,055.00. Following the completion of the purchase, the chief executive officer directly owned 680,251 shares in the company, valued at $16,523,296.79. This represents a 13.23% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark S. Livingston sold 21,303 shares of the company's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the transaction, the chief financial officer directly owned 48,358 shares in the company, valued at $1,233,129. This represents a 30.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 22,046 shares of company stock valued at $561,691 over the last three months. Company insiders own 9.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Peter Anevski 在 11 月 13 日的交易中购买了 79,500 股该股票。每股平均购买价格为 24.29 美元，总交易额为 1,931,055.00 美元。购买完成后，首席执行官直接持有该公司 680,251 股，价值 16,523,296.79 美元。这代表其持股比例增加了 13.23%。该交易已在向 SEC 提交的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Mark S. Livingston 在 11 月 17 日的交易中出售了 21,303 股公司的股票。每股平均售价为 25.50 美元，总价值为 543,226.50 美元。交易完成后，首席财务官直接持有该公司 48,358 股，价值 1,233,129 美元。这代表其持股比例减少了 30.58%。该销售的披露信息可在 SEC 文件中找到。内部人士在过去三个月内出售了价值 561,691 美元的 22,046 股公司股票。公司内部人士持有公司 9.40% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Progyny</h2>
<div class="lb-trans"><h2>对 Progyny 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nordea Investment Management AB grew its stake in Progyny by 0.6% in the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company's stock valued at $4,052,000 after buying an additional 1,140 shares in the last quarter. Cresset Asset Management LLC lifted its position in shares of Progyny by 715.3% during the second quarter. Cresset Asset Management LLC now owns 85,053 shares of the company's stock worth $1,871,000 after acquiring an additional 74,621 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of Progyny by 258.2% in the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company's stock worth $4,144,000 after acquiring an additional 133,703 shares during the period. Millennium Management LLC grew its position in shares of Progyny by 7.5% in the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company's stock valued at $29,107,000 after purchasing an additional 90,367 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Progyny by 243.6% during the 1st quarter. Acadian Asset Management LLC now owns 205,650 shares of the company's stock valued at $4,589,000 after purchasing an additional 145,802 shares during the period. Institutional investors own 94.93% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Nordea Investment Management AB 在第二季度将其在 Progyny 的持股增加了 0.6%。Nordea Investment Management AB 目前持有 183,362 股该公司股票，价值 4,052,000 美元，此前在上个季度又购买了 1,140 股。Cresset Asset Management LLC 在第二季度将其在 Progyny 的持股增加了 715.3%。Cresset Asset Management LLC 目前持有 85,053 股该公司股票，价值 1,871,000 美元，此前在上个季度又收购了 74,621 股。Voya Investment Management LLC 在第一季度将其在 Progyny 的持股增加了 258.2%。Voya Investment Management LLC 目前持有 185,495 股该公司股票，价值 4,144,000 美元，此前在该期间又收购了 133,703 股。Millennium Management LLC 在第一季度将其在 Progyny 的持股增加了 7.5%。Millennium Management LLC 目前持有 1,302,890 股该公司股票，价值 29,107,000 美元，此前在上个季度又购买了 90,367 股。最后，Acadian Asset Management LLC 在第一季度将其在 Progyny 的持股增加了 243.6%。Acadian Asset Management LLC 目前持有 205,650 股该公司股票，价值 4,589,000 美元，此前在该期间又购买了 145,802 股。机构投资者持有公司 94.93% 的股份。</p>
</div><h2>About Progyny</h2>
<div class="lb-trans"><h2>关于 Progyny</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.</p>
<div class="lb-trans"><p>Progyny, Inc 是一家总部位于纽约的生育福利管理公司，与雇主和健康计划合作，设计和管理全面的家庭建设项目。该公司的数字健康平台整合了临床专业知识、患者支持工具和数据分析，帮助会员导航生育治疗，从体外受精（IVF）和卵子冷冻到代孕和收养。通过关注基于结果的护理，Progyny 旨在提高成功率，同时控制客户的成本。</p>
</div><p>The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.</p>
<div class="lb-trans"><p>Progyny 的核心产品是其专有的 Smart Cycle®福利，将临床、情感和后勤支持整合为一个整体。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Progyny</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Progyny</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>Nike 在盈利上超出预期，但在中国市场面临挑战并遭遇关税</li>
<li>低市盈率成长股：开启投资机会</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>股票中的跳空上涨意味着什么？如何利用跳空</li>
<li>2026 年四只高潜力 ETF：小盘股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=PGNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Progyny Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Progyny 吗？</h2>
</div><p>Before you consider Progyny, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Progyny 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Progyny 并不在名单上。</p>
</div><p>While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Progyny 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

华尔街禅将 Progyny（NASDAQ:PGNY）的评级下调至持有